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Abstract
Objective To test the hypotheses that blood biomarkers for nervous system injury, serum concentrations of neurofilament 
light chain protein (NfL) and glial fibrillary acidic protein (GFAp) can serve as biomarkers for disease severity in COVID-
19 patients.
Methods Forty-seven inpatients with confirmed COVID-19 had blood samples drawn on admission for assessing serum 
biomarkers of CNS injury by Single molecule array (Simoa), NfL and GFAp. Concentrations of NfL and GFAp were analyzed 
in relation to symptoms, clinical signs, inflammatory biomarkers and clinical outcomes. We used multivariate linear models 
to test for differences in biomarker concentrations in the subgroups, accounting for confounding effects.
Results In total, 21% (n = 10) of the patients were admitted to an intensive care unit, and the overall mortality rate was 
13% (n = 6). Non-survivors had higher serum concentrations of NfL (p < 0.001) upon admission than patients who were 
discharged alive both in adjusted analyses (p = 2.6 ×  10–7) and unadjusted analyses (p = 0.001). The concentrations of NfL 
in non-survivors increased over repeated measurements; whereas, the concentrations in survivors were stable. The GFAp 
concentration was also significantly higher in non-survivors than survivors (p = 0.02).
Conclusion Increased concentrations of NfL and GFAp in COVID-19 patients on admission may indicate increased mor-
tality risk. Measurement of blood biomarkers for nervous system injury can be useful to detect and monitor CNS injury in 
COVID-19.
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Abbreviations
CNS  Central nervous system
SARS-CoV-2  Severe acute respiratory syndrome corona-
virus 2
ACE-2  Angiotensin-converting enzyme 2
NfL  Neurofilament light protein
GFAp  Glial fibrillary acidic protein
Introduction
Emerging evidence suggest that respiratory syndrome coro-
navirus 2 (SARS-CoV-2) infection may affect the nervous 
system [1, 2]. Increasing numbers of patients with COVID-
19 are reported to have neurologic, neuropsychological 
and neuropsychiatric symptoms and manifestations [1, 
3–5]. Possible mechanisms for nervous system affection 
in COVID-19 have been suggested such as direct infection 
of the nervous system and inflammatory and autoimmune 
mechanisms [6–10], but the pathobiology is still incom-
pletely known [11].
Early identification of central nervous system (CNS) 
manifestation may guide treatment algorithms and thereby 
improve clinical outcome. Meticulous neurological monitor-
ing is important to assess the frequency and degree of nerv-
ous system affections in COVID-19 patients. Blood-based 
biomarkers for CNS injury, like neurofilament light chain 
protein (NfL) and Glial fibrillary acidic protein (GFAp), may 
be valuable tools for detection and monitoring manifesta-
tion during the acute phase of this infection. GFAp is an 
intermediate filament highly expressed in astrocytes and is 
increasingly used as a serum biomarker of astrocytic activa-
tion/injury [12]. NfL is a subunit of neurofilaments, which 
are cylindrical proteins exclusively located in the neuronal 
axons, that can be measured in blood as a marker of neu-
ronal injury [13, 14]. In a recent study, neurochemical evi-
dence of neuronal injury and glial activation in patients with 
moderate and severe COVID-19 infection was demonstrated 
by assessment of NfL and GFAp [15, 16]. However, more 
studies are required to clarify the nature of CNS injury and 
evaluate the usefulness of these biomarkers in COVID-19 
patients.
The aim of this study was to explore the association 
between disease severity in COVID-19 patients and blood 
concentrations of NfL and GFAp.
Methods
Study population
This study includes 47 adult patients (≥ 18  years old) 
with COVID-19, as assessed by a positive SARS-CoV-2 
polymerase chain reaction (PCR) test targeting the E-gene on 
oro- and nasopharyngeal specimens. The patients were con-
secutively recruited from Oslo University Hospital (n = 26) 
and Drammen Hospital, Vestre Viken Hospital Trust (n = 21) 
between March 6 and May 22 2020 to a clinical cohort study 
(Norwegian SARS-CoV-2 study; ClinicalTrials.gov, num-
ber NCT04381819). Clinical information including National 
Early Warning Score (NEWS) 2 and routine laboratory sam-
ples were for most cases collected within 48 h after hospi-
talization. Peripheral blood samples were drawn at inclusion, 
days 2–5 and days 7–10 during hospitalization and repeated 
later for patients who were hospitalized longer. Only patients 
with both clinical data and blood samples available for neu-
rofilament analyses were included. Data were extracted from 
medical charts. Standardized neurological examinations 
were not performed. Using a modified version of the Inter-
national Severe Acute Respiratory and emerging Infection 
Consortium (ISARIC)/World Health Organization (WHO) 
Clinical Characterization Protocol (CCP), clinical and rou-
tine data were abstracted from electronic medical records 
and deposited into an ISARIC (https:// isaric. tghn. org) RED-
Cap database (Research Electronic Data Capture, Vanderbilt 
University, TN, hosted by University of Oxford, UK).
Sample processing and analyses of biomarkers
Serum samples were collected with 4 mL  Vacuette® (Greiner 
bio-one International) and processed within 1 h by centrifu-
gation at 2000 g for 10 min at room temperature. Serum 
aliquots were immediately stored at − 80 °C until analy-
sis. Samples were thawed only once during the processing. 
Measurement of GFAp and NfL in serum samples were per-
formed in the Clinical Neurochemistry Laboratory at the 
Sahlgrenska University Hospital, Sweden, by board-certified 
laboratory technicians blind to clinical data. We used com-
mercially available single molecule array (Simoa) assays 
on an HD-X Analyzer (Human Neurology 4‐Plex A assay 
(N4PA advantage kit, 102153), as described by the manufac-
turer (Quanterix, Billerica, MA). A single batch of reagents 
was used; intra-assay coefficients of variation were below 
10% for all analyses. The results of NfL and GFAp were 
compared with age-related reference limits established in 
house from 2000 healthy control individuals at the Clinical 
Neurochemistry Laboratory, Sahlgrenska University Hospi-
tal, Sweden (unpublished data).
Statistical analysis
For statistical analyses, the R software with a common set of 
packages for the purpose was used [17]. Unique multivariate 
linear models were used to test for changes in the levels of 
all biomarkers on admission to address group differences 
in symptoms, clinical signs and outcomes. Age and gender 
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were adjusted for in all linear models as confounding vari-
ables, while creatinine was included in all linear models for 
NfL since creatinine was a significant confounding factor in 
our dataset. To correlate between NfL and GFAp concentra-
tions with levels of the other biomarkers, Pearson’s correla-
tions were conducted. The biomarker data were logarithmic 
transformed to account for the lack of normal distribution. 
For the biomarkers with low resulting levels (between 0 and 
1), a constant of 1 was added to avoid negative log trans-
formed values. All tests were two sided and p values < 0.05 
were considered significant.
Ethical considerations
Informed consents were obtained from all patients or next-
of-kin if patients were incapacitated of giving consent. The 
Table 1  Characteristics of the 
COVID-19 cohort included in 
the study
Baseline
(a) Characteristics n = 47
 Female % (n) 28% (13)
 Age [mean (SD, range), years] 60.3 (16.3, 27–93)
 Days from symptom onset until hospitalization (SD, range) 9.0 (7.7, 0–45)
 Weight [mean (SD, range), kg] 80.1 (16.7, 54–110)
 Height [(SD, range), mean cm] 173.8 (11.0, 160–195)
 BMI [mean (SD, range)] 26.0 (4.6, 18.3–33.8)
 Present and previous smoking % (n) 26 (12)
 National Early Warning Score 2 (SD, range) 4.4. (3.8, 0–16)
 Intensive care unit % (n) 21 (10)
(b) Symptoms and signs
 History of fever % (n) 89 (40)
 Fever [mean, (SD, range), degrees Celsius] 37.9 (1.0, 35.9–39.8)
 Cough % (n) 85 (34)
 Fatigue % (n) 19 (8)
 Anorexia % (n) 42 (8)
(c) Neurological symptoms
 Headache % (n) 37 (14)
 Ageusia % (n) 21 (4)
 Anosmia % (n) 16 (3)
 Confusion % (n) 13 (6)
 Seizures % (n) 2 (1)
 Meningitis/encephalitis % (n) 5 (1)
 Known dementia % (n) 6 (3)
 Stroke % (n) 0 (0)
(d) Musculoskeletal symptoms
 Myalgia % (n) 68 (26)
 Joint pain % (n) 26 (10)
(e) Biomarkers on admission
 Serum GFAp concentrations [mean (SD, range), pg/mL] 286.4 (221, 74–1212)
 Above cut-off % (n) 48 (22)
 Serum NfL concentrations [mean (SD, range), pg/mL] 33.7 (36.0, 5.8–174.4)
 Above cut-off, % 30 (14)
 CRP [mean (SD, range), mg/L] 97.4 (92.4, 0–400)
 Ferritin [mean (SD, range), µg/L] 952 (747, 21–3465)
 White blood cell count [mean (SD, range), ×  109/L] 6.5 (3.1, 2.6–18.0)
 Procalcitonin [mean (median, SD, range), µg/L] 0.7 (0.1, 2.9, 0–16.3)
 CK [mean (SD, range), U/L] 331.9 (733.4, 19–3572)
 Creatinine [mean (SD, range), µmol/L] 95.8 (51.4, 55–281)
 Neutrophil granulocyte count [mean (SD, range), ×  109/L] 4.8 (27, 1.3–11.3)
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study was approved by the South-Eastern Norway Regional 
Health Authority (reference number: 106624).
Sources of support
This study received funding from Oslo University Hospi-
tal and the Research Council of Norway Grant no 312780 
and has received private donation from Vivaldi Invest A/S 
owned by Jon Stephenson von Tetzchner.
Results
Baseline characteristics
The mean age of the included 47 patients was 60.3 (SD 
16.3, range 27–93) years and the male proportion was 72% 
(n = 34) (Table 1). On average, the patients had symptoms 
of COVID-19 infection for nine days (range 0–45) before 
hospitalization. The most common neurological symptoms 
among all patients were headache, ageusia, anosmia and 
confusion (Table 1). None of them had reported chronic 
neurological diseases. Mean NEWS2 was 4.4 (range 0–16) 
and significantly higher among non-survivors (Table 1 and 
Fig. 3). In total, 21% (n = 10) of the patients were admitted 
to an intensive care unit (ICU). Six patients (13%) died from 
COVID-19 during the hospital stay (Table 1).
Serum concentrations of NfL and GFAp in COVID‑19 
patients
On admission, concentrations of NfL and GFAp above refer-
ence limits were measured in 30% (n = 14) and 48% (n = 22) 
of the COVID-19 patients, respectively (Table 1). Correla-
tions between NfL concentration and GFAp (p = 2.2 ×  10–7), 
procalcitonin (p = 0.001), creatinine (p < 0.001) and neu-
trophil granulocyte count (p = 0.01) as well NEWS2 score 
(p = 0.04) were found. No correlation was detected between 
NfL and GFAp with CRP, creatine kinase, ferritin or white 
blood cell count (Fig. 1). GFAp concentrations were only 
associated with NfL concentrations (Fig. 2, Table 2).
Concentrations of NfL and GFAp in relation 
to clinical outcome
Concentrations of NfL were significantly higher in non-
survivors (n = 6) compared to survivors (p = 2.6 ×  10–7) 
when adjusting for age and creatinine levels on admission 
(Fig. 3). Furthermore, higher concentrations of GFAp were 
significantly associated with a non-favorable disease out-
come (p = 0.02) (Table 3). Significant differences among 
non-survivors compared to survivors were also observed in 
the adjusted linear models for the level of GFAp (p = 0.02), 
CRP (p = 0.02), creatine kinase (p = 0.02) and procalcitonin 
(p = 0.003) on admission but was not observed for the other 
biomarkers (creatinine or neutrophil granulocyte count) 
(Figs. 2, 3).
The longitudinal measurements of NfL concentration 
in patients available for this follow-up showed increased 
serum concentrations of NfL at hospital admittance and 
further increased concentrations during hospitalization in 
patients who died of COVID-19 (Fig. 4). The patients with 
the highest concentrations of NfL (> 120, max 464 pg/mL) 
had severe disease course resulting in death during hos-
pitalization. They were all admitted with both respiratory 
and neurological symptoms (headache, dizziness) 4–7 days 
after disease onset. x The concentrations of NfL generally 
increased during the disease course in these subjects.
Discussion
This pilot study indicates that increased concentrations of 
serum NfL in patients with COVID-19 may be a predictor 
of a severe disease course and increased mortality GFAp 
was also significantly associated with mortality. Increased 
NfL and GFAp concentration in patients with COVID-19 
can be presumed to reflect affection of the nervous system. 
Although both the peripheral and central nervous system 
contain NfL, the correlation between CSF and blood is so 
strong that the majority of the NfL concentration must come 
from the CNS [18, 19]. Furthermore, GFAp is considered 
to be fairly specific to CNS [20]. The findings of high con-
centrations of NfL in non-survivors should be further stud-
ied in larger COVID-19 cohorts. Our findings are in line 
with another recent study of serum NfL concentrations in 
critically ill ICU patients where NfL concentrations were 
higher in COVID-19 patients than non-COVID-19 patients. 
Furthermore, higher NfL levels were associated with unfa-
vorable short-term outcome [21].
Fig. 1  An overview of Pearson’s correlation between NfL concen-
trations and other biomarkers. Depicted are the correlations between 
NfL and GFAp concentrations (a), CRP (b), white blood cell count 
(c), procalcitonin (d), creatinine (e), creatine kinase (f), neutrophil 
granulocyte count (g) and National Early Warning Score (NEWS) 2 
(h). Depicted are the logarithmic transformed values
◂
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Of other biomarkers available in this study, increased 
levels of procalcitonin were apparently associated with 
increased concentrations of NfL. However, this result is 
influenced by a few patients with very high measurements. 
Thus, the implications of these findings are not clear. Inter-
estingly, NfL concentrations were not correlated with CRP 
and ferritin, often found to be associated hyperinflamma-
tion in COVID-19 patients, suggesting that the raised NfL 
concentrations merely reflect enhanced inflammation.
The association between clinical symptoms and NfL 
and GFAP in this study must be assessed with caution as 
the sample size was small. The patients with highest NfL 
values did all present with headache. Further neurological 
examination and evaluation was not available as they were 
all intubated shortly after admission. Furthermore, neuroim-
aging data were not available. The sample size was too small 
to draw other conclusions than fatal outcome. The lack of 
neurological examinations and of neuroimaging data does 
not allow to take in account the correlation with neurologi-
cal involvement.
The identification of biomarkers in blood to assess nerv-
ous system manifestation will be important to monitor the 
severity of the disease and optimize treatment in COVID-19 
patients. Measurement of NfL and GFAp in blood can be 
clinically useful methods to assess neurological affection in 
COVID-19, since this can easily be managed despite medi-
cal isolation procedures. Although NfL has been shown to be 
useful as diagnostic, prognostic and monitoring biomarker in 
a wide range of other neurological conditions [19, 22–24], 
more studies are needed to assess the applicability of NfL 
in COVID-19.
One could claim that the high concentrations of NfL 
could reflect medications used in ICU. However, a recent 
study of NfL and other blood biomarkers in patients under-
going inhalation general anesthesia showed a decrease in 
NfL concentrations after 5 h compared to baseline. This may 
suggest that the levels of NfL in COVID-19 patients treated 
in ICU might be even larger in magnitude but are masked by 
anesthesia-induced decreases [25].
The identification of biomarkers in blood to assess 
nervous system manifestation is important to monitor 
the severity of the disease and optimize treatment in 
COVID-19 patients. Measurement of NfL in blood can 
be a clinically useful tool to assess neurological affection 
in COVID-19. Although NfL has been shown to be useful 
as diagnostic, prognostic and monitoring biomarker in a 
wide range of other neurological conditions [19, 22–24], 
more studies are needed to assess the applicability of NfL 
in COVID-19.
In this pilot study, there are several limitations. First, the 
number of patients with full data sets available in this study 
was modest. Second, detailed and systematic neurological, 
neurophysiological and neuroradiological investigations 
were not possible to perform, since our patients were treated 
under medical isolation procedures at different units and sev-
eral patients needed ventilatory support in ICUs. Thus, pos-
sible association between GFAp and NfL and specific CNS 
manifestations may have been undetected in this study. How-
ever, none of the patients with elevated NfL and GFAP lev-
els had reported chronic neurological disorders. To expand 
our knowledge on the association between NfL and GFAp 
with neurological symptoms, we plan a follow-up study of 
COVID-19 patients up to a year after diagnosis including a 
systematic neurological assessment.
In conclusion, elevated concentrations of NfL and 
GFAp in COVID-19 patients seem to be potential prog-
nostic markers in COVID-19. Further studies are essential 
to elucidate the pathogenesis and the clinical importance 
of how the COVID-19 disease affects the peripheral and 
CNS and how this can be measured and treated. Prospec-
tive neurologic and cognitive assessment of individuals 
with COVID-19 will also be crucial to understand the nat-
ural history of COVID-19 in the central nervous system 
and monitor for any long-term neurologic sequelae [26].
Fig. 2  An overview of Pearson’s correlation between GFAp concen-
trations and other biomarkers. Depicted are the correlations between 
GFAp concentrations and NfL concentrations (a), CRP (b), white 
blood cell count (c), procalcitonin (d), creatinine (e), creatine kinase 
(f), neutrophil granulocyte count (g) and National Early Warning 
Score (NEWS) 2 (h). Depicted are the logarithmic transformed values
◂
Table 2  Differences in NfL concentrations related to symptoms, 
treatment and outcome
Symptom Linear regression, adjusting for 
age and creatinine (R2 = 0.26)
t R2 p
Cough 3.16 0.38 3.1 × 10–3
Fatigue 2.50 0.34 0.02
Ventilatory support 1.40 0.28 0.17
Outcome—died − 6.13 0.60 2.6 × 10–7
Anorexia − 1.24 0.46 0.23
Confusion − 0.95 0.26 0.35
Myalgia 3.59 0.42 8.7 × 10–4
Joint pain 2.86 0.37 6.6 × 10–3
Fever − 0.37 0.24 0.72
Headache 1.73 0.29 0.09
Ageusia − 1.54 0.48 0.14
Anosmia 0.06 0.41 0.95
Present and previous smoking − 0.34 0.49 0.73
Intensive care unit − 1.93 0.30 0.06
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Fig. 3  Levels of biomarkers among patients who died and who sur-
vived COVID-19 in this study. Statistical analyses performed with 
unique linear models adjusting for confounding effects. a NfL con-
centrations, b GFAp concentrations, c CRP, d National Early Warn-
ing Score (NEWS) 2, e creatinine, f creatine kinase, g neutrophil 
granulocyte count and h procalcitonin
◂
Table 3  Differences in GFAp concentrations related to symptoms, 
treatment and outcome
Symptom Linear regression, adjusting for 
age (R2 = 0.40)
t R2 p
Cough 0.57 0.37 0.58
Fatigue 1.81 0.43 0.08
Ventilatory support − 0.95 0.40 0.35
Outcome—died − 2.40 0.46 0.02
Anorexia − 0.22 0.52 0.83
Confusion − 1.44 0.42 0.16
Myalgia 1.86 0.44 0.07
Joint pain 1.78 0.43 0.08
Fever 0.37 0.39 0.72
Headache − 0.26 0.39 0.80
Ageusia 0.00 0.52 1.00
Anosmia 0.70 0.53 0.49
Present and previous smoking − 0.33 0.39 0.75
Intensive care unit 0.44 0.39 0.66
Fig. 4  Longitudinal assessment of NfL concentrations among 
patients who died and who survived COVID-19 in this study. a Four 
subjects with longitudinal data who died. b An overview of the sub-
jects who were discharged alive after hospitalization. Only subjects 
with longitudinal data are depicted
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